Treatment Choices Are Limited, but Oncologists’ Receptivity to Targeted Agents Presents a Lucrative Opportunity The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/Chugai…
Treatment Choices Are Limited, but Oncologists’ Receptivity to Targeted Agents Presents a Lucrative Opportunity The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/Chugai…
What attributes will distinguish emerging therapies in the eyes of oncologists and payers? Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for…
What attributes will distinguish emerging therapies in the eyes of oncologists and payers? Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for…
Treatment for breast cancer (CaB) in the United States has matured as oncologists have formalized protocols around specific patient populations, namely HER2+, HR+/HER2-, and HR-/HER2- (also known…
LaunchTrends®: Perjeta and Kadcyla is a series of four post-launch syndicated reports designed to track physician perception and uptake of newly launched Perjeta (Roche/Genentech’s pertuzumab)…
Oncology prescribing has changed with the broad adoption of clinical pathways programs, bundled payment arrangements, and accountable care organizations (ACOs). Each of these managed care reforms…
LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer…
Last Updated 13 December 2013 The prostate cancer market has witnessed considerable changes over the last three years, owing to the launch of five new therapies for treatment of metastatic castrate…